Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis
Reihaneh Abolhassani-Chimeh, Onno W. Akkerman, Antonia Morita Iswari Saktiawati, Nieko Punt, Mathieu S. Bolhuis, Yanri Wijayanti Subronto, Sumardi Sumardi, Tjip S. van der Werf, Jos G. W. Kosterink, Jan‐Willem C. Alffenaar, Marieke G. G. Sturkenboom
Abstract
= 10,000). External validation showed LSS with time points 0 h, 2 h, and 6 h performed best with RMSE of 9.90% and bias of 0.06%. Food slowed absorption of pyrazinamide, but did not affect bioavailability, which may be advantageous in case of nausea or vomiting in which food can be used to diminish these effects. In this study, we successfully developed and validated a popPK model and LSS, using 0 h, 2 h, and 6 h postdose samples, that could be used to perform therapeutic drug monitoring (TDM) of pyrazinamide in TB patients.